In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals Of The Week: Amgen/Watson, Baxter/Momenta, Takeda/Intellikine

Executive Summary

Biosimilars took center stage during the last two weeks of 2011, as Amgen and Watson and then Baxter and Momenta followed up on the collaboration between Biogen Idec and Samsung BioLogics earlier in the month.

You may also be interested in...



Micro-Partnerships With Academia Helping To Drive Bristol’s Pipeline Development

New agreement with Duke Translational Medicine Institute highlights Bristol-Myers Squibb’s particular approach to collaborating with academia – small, low-money partnerships that get pharma and university scientists working together in an atmosphere virtually free of corporate bureaucracy.

Takeda Adds To Oncology Holdings By Purchasing Intellikine And Two PI3K Clinical Candidates

Takeda’s Millennium oncology unit will absorb Intellikine’s programs in a deal paying $190 million upfront to buy out the privately held biotech.

AstraZeneca Strengthens Diabetes R&D With Option On Prosidion's Early-Stage Compounds

AstraZeneca has entered into an option agreement on Prosidion's first-in-class GPR119 receptor agonists for diabetes.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS054060

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel